Table 5.
Subgroup analysis of CTA expression in patients treated with or without postoperative adjuvant chemotherapy
| Variables | Without Chemo-
|
With Chemo-
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis
|
Multivariate analysis
|
Univariate analysis
|
Multivariate analysis
|
|||||||||
| O/N | % | P | 95% CI | HR | P | O/N | % | P | 95% CI | HR | P | |
| Sex | 0.099 | 0.349–1.582 | 0.743 | 0.441 | 0.912 | |||||||
| Male | 36/65 | 55.4 | 23/67 | 34.3 | ||||||||
| Female | 12/31 | 38.7 | 13/37 | 35.1 | ||||||||
| Age (years) | 0.245 | 0.378 | ||||||||||
| <65 | 33/70 | 47.1 | 31/93 | 33.3 | ||||||||
| ≥65 | 15/26 | 57.7 | 5/11 | 45.5 | ||||||||
| Smoking history | 0.092 | 0.685–2.958 | 1.423 | 0.344 | 0.174 | 0.321–1.189 | 0.617 | 0.149 | ||||
| No | 14/33 | 42.4 | 18/44 | 40.9 | ||||||||
| Yes | 34/63 | 54.0 | 18/60 | 30.0 | ||||||||
| Thoracic radiotherapy | 0.183 | 0.045–2.374 | 0.326 | 0.269 | 0.707 | |||||||
| No | 47/90 | 52.2 | 31/86 | 36.0 | ||||||||
| Yes | 1/6 | 16.7 | 5/18 | 27.8 | ||||||||
| Pathology | 0.320 | 0.313 | ||||||||||
| ADC | 22/48 | 45.8 | 20/52 | 38.5 | ||||||||
| SCC | 26/48 | 54.2 | 16/52 | 30.8 | ||||||||
| TNM stage | 0.565 | 0.019 | 1.160–5.063 | 2.423 | 0.019 | |||||||
| IIIA | 34/70 | 48.6 | 26/83 | 31.3 | ||||||||
| IIIB | 14/26 | 53.9 | 10/21 | 47.6 | ||||||||
| MAGEA1 | 0.980 | 0.203 | ||||||||||
| Negative | 19/41 | 46.3 | 10/39 | 25.6 | ||||||||
| Positive | 29/55 | 52.7 | 26/65 | 40.0 | ||||||||
| MAGEA3 | 0.080 | 1.055–4.008 | 2.056 | 0.034 | 0.312 | |||||||
| Negative | 35/76 | 46.1 | 27/73 | 37.0 | ||||||||
| Positive | 13/20 | 65.0 | 9/31 | 29.0 | ||||||||
| MAGEA10 | 0.473 | 0.270 | ||||||||||
| Negative | 26/49 | 53.1 | 20/51 | 39.2 | ||||||||
| Positive | 22/47 | 46.8 | 16/53 | 30.2 | ||||||||
| MAGEB2 | 0.912 | 0.379 | ||||||||||
| Negative | 34/66 | 51.5 | 25/65 | 38.5 | ||||||||
| Positive | 14/30 | 46.7 | 11/39 | 28.2 | ||||||||
| MAGEC1 | 0.283 | 0.653 | ||||||||||
| Negative | 26/50 | 52.0 | 20/57 | 35.1 | ||||||||
| Positive | 22/46 | 47.8 | 16/47 | 34.0 | ||||||||
| XAGE1 | 0.078 | 0.260–0.968 | 0.502 | 0.040 | 0.753 | |||||||
| Negative | 35/61 | 57.4 | 24/66 | 36.4 | ||||||||
| Positive | 13/35 | 37.1 | 12/38 | 31.6 | ||||||||
| KK-LC-1 | 0.408 | 0.392 | ||||||||||
| Negative | 24/56 | 42.9 | 15/49 | 30.6 | ||||||||
| Positive | 24/40 | 60.0 | 21/55 | 38.2 | ||||||||
| CTAG1A/B | 0.687 | 0.677 | ||||||||||
| Negative | 29/60 | 48.3 | 23/70 | 32.9 | ||||||||
| Positive | 19/36 | 52.8 | 13/34 | 38.2 | ||||||||
| VCX1 | 0.343 | 0.302 | ||||||||||
| Negative | 39/82 | 47.6 | 20/65 | 30.8 | ||||||||
| Positive | 9/14 | 64.3 | 16/39 | 41.0 | ||||||||
| VCX3A | 0.840 | 0.946 | ||||||||||
| Negative | 38/75 | 50.7 | 25/71 | 35.2 | ||||||||
| Positive | 10/21 | 47.6 | 11/33 | 33.3 | ||||||||
Note: Only factors with a P-value <0.05 are labeled as bolded numbers.
Abbreviations: CTA, cancer/testis antigen; Chemo-, chemotherapy; CI, confidence interval; HR, hazard ratio; ADC, adenocarcinoma; SCC, squamous cell carcinoma; O/N, observed death number/total patient number in each group.